by Virus filtration products provide a crucial method for ensuring safety and purity standards in the life sciences sector. These filtration products are essential for trapping potential viral contaminants within biotherapeutic medications, vaccines, and other injectable drugs intended for human administration. With the exponential rise in development and production of complex biologics such as monoclonal antibodies, gene therapy vectors and other cutting-edge biopharmaceuticals, the need for robust virus removal steps within downstream processing workflows has never been more acute.
The global Virus Filtration Market is estimated to be valued at US$ 5.86 Mn in 2024 and is expected to exhibit a CAGR of 3.1% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the primary trends paving the way for future growth within the virus filtration industry is the ongoing partnership activity between device manufacturers and end-user biopharma companies. As biopharmaceutical pipelines expand and industry standards for product safety requirements are tightened globally, device makers are increasingly working in tandem with drug developers to optimize filtration solutions. Another noticeable trend is the onset of single-use virus filtration systems that allow for disposable, closed-processing workflows. These single-use virus filters are time and cost effective while minimizing cross-contamination risks compared to traditional stainless-steel housings. The emergence of novel virus-host interactions uncovered due to the COVID-19 pandemic have also provoked more exhaustive virus screening practices during drug development. All of these factors are expected to drive continued demand for both upstream and downstream virus removal technologies across the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate. The costs involved in research and development of virus filtration techniques is quite high. In addition, established players have strong brand recognition and distribution networks.
Bargaining power of buyers: The bargaining power of buyers is moderate. The availability of substitutes provides buyers with some bargaining power. However, specialized nature of virus filtration solutions limits bargaining power.
Bargaining power of suppliers: The bargaining power of suppliers is low to moderate. The key raw materials used in virus filtration are commoditized in nature. There are also multiple supplier options available.
Threat of new substitutes: The threat of new substitutes is moderate. While new tools for virus clearance are being developed, virus filtration is still considered the gold standard in the industry.
Competitive rivalry: The competitive rivalry is high. Key players compete based on technologies, product quality, and service. They also engage in mergers and acquisitions for diversification and market share expansion.
Key Takeaways
The Global Virus Filtration Market Size is expected to witness high growth over the forecast period of 2024 to 2031. The global Virus Filtration Market is estimated to be valued at US$ 5.86 Mn in 2024 and is expected to exhibit a CAGR of 3.1% over the forecast period 2024 to 2031.
Regionally, North America is expected to dominate the market owing to high investment in R&D by key players and strong healthcare infrastructure supporting clinical research activities in the region. Europe and Asia Pacific are also expected to exhibit substantial growth.
Key players operating in the virus filtration market are Astellas Pharma, Genzyme Corporation, and Accord Healthcare Ltd. Astellas Pharma is a leading player with strong presence across key markets. Genzyme Corporation offers a wide portfolio of virus filtration systems and solutions. Accord Healthcare Ltd specializes in generics and has a growing share in biologics drug manufacturing.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
